• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biocept Inc (NQ: BIOC )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Oct 24, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Biocept Inc

    < Previous 1 2 3 4 5 6 Next >
    Biocept Reports Second Quarter 2022 Financial Results
    From Biocept, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. 
    Via Benzinga
    Biocept to Present at the LD Micro Main Event XV
    From Biocept, Inc.
    Via Business Wire
    Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
    From Biocept, Inc.
    Via Business Wire
    Recap: Biocept Q4 Earnings
      Biocept (NASDAQ:BIOC) reported its Q4 earnings results on Wednesday, April 6, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
    From Biocept, Inc.
    Via Business Wire
    Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
    From Biocept, Inc.
    Via Business Wire
    Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
    Gainers 
    Via Benzinga
    Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
    Gainers 
    Via Benzinga
    Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Biocept, Inc.
    Via Business Wire
    Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
    From Biocept, Inc.
    Via Business Wire
    Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
    From Biocept, Inc.
    Via Business Wire
    Biocept Appoints RSM as Independent Auditor
    From Biocept, Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Monday
    During Monday's session, 77 companies made new 52-week lows. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
    On Friday, 61 companies hit new 52-week lows. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Gainers 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Gainers 
    Via Benzinga
    Biocept to Hold Business Strategy Conference Call Today
    From Biocept, Inc.
    Via Business Wire
    Biocept's Return On Capital Employed Overview
    According to Benzinga Pro data, during Q1, Biocept (NASDAQ:BIOC) posted sales of $19.95 million. Earnings were up 6.84%, but Biocept still reported an overall loss of $2.77 million. 
    Via Benzinga
    Biocept Reports First Quarter 2022 Financial Results
    From Biocept, Inc.
    Via Business Wire
    The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
    Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
    Via Benzinga
    Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Biocept, Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Wednesday
    On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
    Via Benzinga
    Looking Into Biocept's Return On Capital Employed
    Benzinga Pro data, Biocept (NASDAQ:BIOC) reported Q4 sales of $13.98 million. Earnings fell to a loss of $2.97 million, resulting in a 375.6% decrease from last quarter. 
    Via Benzinga
    Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
    From Biocept, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Earnings Scheduled For March 31, 2022
    Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.